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Takotsubo cardiomyopathy (TC) is a rare complication of 
electroconvulsive therapy (ECT), an effective and safe treat-
ment for severe cases of depression and psychosis. There 
are reports on 16 patients who developed TC after ECT, and 
these were predominantly female patients treated with 
antidepressants for depressive disorder. We describe a case 
of a 40-year-old male patient, with a history of schizophre-
nia and heavy caffeine and nicotine use, treated for acute 
psychotic episode with haloperidol and clozapine. Pro-
pranolol was administered because of clozapine-induced 
tachycardia. After 8 weeks without therapeutic response, 
the patient was referred for standard ECT procedure, which 
included premedication and bifrontotemporal stimulation. 
Two hours later, the patient experienced gastric pain and 
had increased troponin and natriuretic peptide levels and 
ST-elevation. After inotrope and anticoagulant treatment 
and replacement of antipsychotics, the patient remained 
stable. Contrary to common opinion, previous adrenergic 
blockade in this patient did not prevent TC occurrence. TC 
pathophysiology remains unclear although it has been re-
lated to the burst of norepinephrine neurons. Psychosis 
has also been associated with catecholamine dysfunction, 
and excessive psychological stress with long-term nore-
pinephrine dysfunction. Animal models have shown that 
ECT, clozapine, and nicotine and caffeine use could consid-
erably increase catecholamine levels. Clinical understand-
ing of rare cardiac ECT complications could improve early 
recognition of patients at risk for TC and ensure safe ECT 
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Takotsubo cardiomyopathy is a rare complication of elec-
troconvulsive therapy (ECT), an effective and safe treat-
ment for severe depression and psychosis (1). It has been 
suggested that catecholamines play a role in takotsubo 
cardiomyopathy development (2).
CaSe repOrt
A 40-year-old white man, severely addicted to nicotine 
and caffeine, without alcohol misuse history, was admit-
ted to our psychiatry department in December 2017 due 
to positive psychotic symptoms and was prescribed halo-
peridol (30 mg/d), promazine (300 mg/d), and diazepam 
(30 mg/d). He and his family members denied the history 
of medical conditions, and no medical data on his earli-
er treatment were found in our hospital’s archives. Three 
weeks later, because of treatment resistance, haloperidol 
and promazine were discontinued, and clozapine was aug-
mented to a final dose of 350 mg a day. On the sixth day of 
clozapine therapy, the patient developed tachycardia and 
was given propranolol (40 mg/d) for cardioprotection. As 
psychosis did not improve by the end of the week 8, ECT 
was indicated.
Informed consent and ethical approval for ECT applica-
tion were obtained from the University Hospital Centre Za-
greb. The patient also signed informed consent for medical 
data publication. Somatic and psychiatric pre-evaluation 
revealed no contraindications for ECT. The blood pressure 
was 110/70 mm Hg, heart rate 92/min, axillary tempera-
ture 36.0°C, and electrocardiogram (ECG) showed a sinus 
rhythm with intermediate axis without any abnormalities. 
ECT was first applied at week 10. Diazepam was discontin-
ued. Atropine, propofol, and succinylcholine were admin-
istered as standard premedication. The electrical dose was 
titrated to the patient’s seizure threshold at 0.5-millisecond 
pulse width, 20-Hz frequency, 5.6-second stimulus duration, 
and 900-mA current using Thymatron® System IV (Somatics 
LLC, Chatham, IL, USA), and bifrontotemporal stimulation 
was applied. Two hours after ECT, the patient complained 
of gastric pain. He was pale and tachypnoic, without a pal-
pable radial pulse. Initial laboratory tests showed the tro-
ponin T level of 1956 ng/L (reference range <14 ng/L) and 
N-terminal pro-b-type natriuretic peptide (NT-pro BNP) 
of 12 409ng/L (reference range <300 ng/L). ECG showed 
marked ST-elevation, with Q waves and deep symmetrical 
T wave inversion in anterior leads, along with QTc inter-
val prolongation (525 ms), indicating possible acute an-
terior wall myocardial infarction. However, the patient 
denied chest pain and complained of shortness of 
breath. The echocardiographic exam revealed severely re-
duced left ventricle ejection fraction (15%), with only later-
al wall contracting and a consequent apical thrombus. The 
patient was immediately transferred to the Coronary Care 
Unit, where he was treated with continuous intravenous in-
fusion of dobutamine (4 µg/min/kg) and furosemide (250 
mg/d). Beside these, loading doses of aspirin (300 mg) and 
clopidogrel (600 mg), and low molecular weight heparin in 
full dose, were administered as standard therapy for suspi-
cious acute myocardial infarction before planned coronar-
ography. Clozapine was discontinued, and haloperidol (30 
mg/d) and diazepam (30 mg/d) were induced intramus-
cularly. The patient refused the recommended coronary 
angiography and was distrustful to all other proposed di-
agnostic procedures. After 24 hours, he was hemodynami-
cally stable, and inotropic support was gradually stopped. 
Heart failure therapy, consisting of eplerenone (25 mg/d) 
and ivabradine (2 × 5 mg/d), was initiated. Serial echocar-
diographic examinations over the next 4 days revealed that 
the left ventricular systolic function completely normal-
ized, and troponin T and NT-proBNP level considerably de-
creased (228 ng/L and 1190 ng/L, respectively). ECG show-
ing sinus rhythm, rate 82/min with a vertical axis, did not 
indicate myocardial ischemia. Based on troponin T and NT-
proBNP levels, echocardiographic findings, ECG, and clinical 
restitution, the patient was diagnosed with takotsubo car-
diomyopathy. He was then transferred back to the psychiat-
ric department. At that time, clopidogrel was discontinued 
as the diagnosis of myocardial infarction seemed unlikely. 
During the next two weeks, echocardiographic exams were 
unremarkable, and troponin T and NT-proBNP levels were 
within the reference range (6 ng/L and 69 ng/L, respec-
tively). By the end of week 12, the patient was referred to a 
chronic psychiatric institution.
DiSCuSSiOn
Our hypothesis was that in our patient clozapine and ECT 
induced catecholamine activity discordant with beta-
blocker effect. Of the 16 reported ECT-induced takotsubo 
cardiomyopathy cases so far, only one was a young male 
patient treated with clozapine, but without concomitant 
beta-blocker therapy (Table 1) (2-16).
Although ECT-related cardiac complications have been 
occasionally reported, takotsubo cardiomyopathy remains 
the least understood among them. Takotsubo cardiomy-
opathy is a transient cardiac syndrome that most often 
involves left ventricular apical akinesis and mimics acute 
coronary syndrome, showing ST-segment elevation and 
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table 1. Case studies about takotsubo cardiomyopathy after the use of electroconvulsive therapy (eCt) ordered by the year of 
publishing.
 
 
Sex
 
 
ethnicity
 
 
age
 
 
Diagnose
 
Main 
therapy
 
Concomitant 
therapy
number of 
eCt applica-
tions
 
 
Comorbidities
alcohol/ 
tobacco/ 
illicit drugs use
Zhu 
1992 
(6)
F Unknown 77 Major depres-
sion
Antidepressant 
therapy
Unknown Not speci-
fied, 1st?
No history of cardiac 
disease
Unknown
Eitzman 
1994 
(7)
F Unknown 76 Severe depres-
sion
Unknown Unknown Unknown No history of medical 
treatment
Unknown
Ring 
1996 
(8)
F Unknown 41 Major depres-
sive dissociative 
disorder
Paroxetine 
80 mg daily, 
naltrexone 200 
mg daily
Propranolol long-
acting 800 mg, 
propranolol 30 mg 
four times daily
1st course;  
1st session
Obesity Unknown
O’Reardon 
2008 
(16)
F Unknown 45 Major depres-
sive disorder
Unknown Warfarin 1st course: 
3rd session
Deep vein throm-
bosis with multiple 
pulmonary emboli, 
obstructive sleep 
apnea, hyperten-
sion, Loeys-Dietz 
syndrome
None
Chandra 
2009 
(12)
F Unknown 70 Depression, 
bipolar disorder
Unknown Unknown Unknown Mitral valve prolapse 
repair
Unknown
Go 
2009 
(9)
F Unknown 50 Major depres-
sion with sui-
cidal ideation
Quetiapine, 
venlafaxine, 
mirtazapine, 
pregabalin
Ropinirole, 
metformin, 
insulin, enalapril, 
hydroxyzine, fex-
ofenadine, aspirin, 
furosemide
Unknown 
course; 3rd 
session
Type 2 diabetes 
mellitus, hyperten-
sion, obesity, asthma, 
sleep apnea, degen-
erative joint disease
Unknown
Go 
2009 
(9)
F Unknown 49 Bipolar 
disorder; a 
depressed state 
with psychotic 
features
Valproate, 
fluoxetine, 
haloperidol, 
quetiapine
Albuterol, flutica-
sone/salmeterol
Unknown Asthma, obesity, dys-
lipidemia, stress in-
continence, impaired 
glucose tolerance
Unknown
Kent 
2009 
(13)
F White 71 The major 
depressive 
episode with 
psychotic 
features
Nortriptyline 
25 mg daily, 
quetiapine 200 
mg daily, lora-
zepam 0.5 mg 
twice daily
Metoprolol 
extended-release 
100 mg twice 
daily, amlodipine 
5 mg twice 
daily, Nonsteroidal 
anti-inflammatory 
medications
3rd course; 
3rd session
Hypertension, costo-
chondritis
Unknown
Satterthwaite 
2009 
(10)
F White 72 Major depres-
sion with 
catatonia
Unknown Unknown 1st course; 
1st session
Unknown Unknown
Beach 
2010 
(1)
F White 52 Treatment-resis-
tant depression
Fluoxetine 
80 mg daily, 
olanzapine 5 
mg daily
Topiramate 200 
mg daily, gabap-
entin 800 mg daily
Not speci-
fied, 1st?
Migraine headaches, 
cholecystectomy
Occasional 
alcohol use
Serby 
2010 
(5)
F White 90 The recurrent 
major depres-
sive disorder
Duloxetine 60 
mg daily
Ranitidine 150 
mg daily, calcium 
carbonate 600 
mg twice daily, 
multivitamin once 
daily
>100 courses 
of ECT; 
mECT* for 
more than 
five years; 3rd 
session
Hypertension (nor-
motensive without 
medication)
Unknown
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cardiac enzyme levels similar to myocardial infarction (17). 
However, in takotsubo cardiomyopathy cardiac angiogra-
phy can confirm no significant coronary artery stenosis. 
Typical echocardiography reveals left ventricular apical 
ballooning (17). Several takotsubo cardiomyopathy causes 
have been proposed, including coronary artery ischemia 
and microvascular spasm (18). The spasm is induced by 
a sudden catecholamine increase since patients with ta-
kotsubo cardiomyopathy have elevated catecholamine 
blood concentrations. Takotsubo cardiomyopathy was also 
strongly associated with mental illnesses (19). Although our 
patient did not undergo angiography, we find takotsubo 
cardiomyopathy a more likely diagnosis than ST-elevation 
myocardial infarction for several reasons. The degree of 
ECG changes observed in the initial ECG, along with a se-
verely reduced left ventricular ejection fraction, would not 
likely resolve in 24 hours in a patient with conservatively 
treated ST elevation myocardial infarction. Furthermore, 
troponin T peak of <2000 ng/L is rarely observed in cases of 
anterior myocardial infarction, even when timely reperfu-
sion is performed. The patient could have stable coronary 
disease due to his significant history of nicotine abuse, 
which might have temporarily worsened ischemia. How-
ever, he never complained of chest pain, either before 
or after the described event. Moreover, it is unlikely 
that transient spasm would cause such echocardiographic 
findings (20). Lastly, deep, symmetric T wave inversion and 
prolonged QTc interval observed in this case are promi-
nent features of takotsubo cardiomyopathy (17).
Most patients with ECT-induced takotsubo cardiomyopa-
thy were women older than 70 treated for major depres-
sion (4-7,10,11,14). Due to hormonal changes, post-meno-
pausal women could be more susceptible to cardiovascular 
events after a sympathetic response to acute stressors, such 
as ECT application (18). However, men show a greater auto-
nomic response to stress than pre-menopausal women of 
the same age (21). Psychosis has been associated with cat-
echolamine dysfunction, and excessive psychological stress 
with long-term norepinephrine dysfunction (22). Therefore, 
positive psychotic symptoms in our patient could have led 
to elevated catecholamine blood concentrations.
Grubisha et al (16) reported on a case of takotsubo car-
diomyopathy after concomitant ECT and clozapine use, 
which points to a synergistic effect of ECT and clozapine. 
Clozapine is a strong antagonist of different subtypes of 
adrenergic, cholinergic, and histaminergic receptors and 
systematically elevates epinephrine and norepinephrine 
levels. Catecholamine hypothesis of ECT-induced takot-
Celano 
2011 
(14)
F Unknown 76 The recurrent 
major depres-
sive disorder
Mirtazapine, 
olanzapine
Unknown 1st course; 
11 sessions 
(1st mECT* 
session)
Multiple myelomas Unknown
Binhas 
2013 
(11)
F Unknown 85 Depression, 
anorexia
Unknown Unknown Unknown 
course; 3rd 
session
Unknown Unknown
Grubisha 
2014 
(3)
M Unknown 31 Schizoaffec-
tive disorder, 
pervasive 
developmental 
disease
Clozapine 350 
mg daily
Zonisamide 2nd course; 
50 treat-
ments
Hypertension, seizure 
disorder
Unknown
Narayanan 
2014 
(15)
F White 74 The recurrent 
major depres-
sive disorder
Venlafaxine, 
mirtazapine, 
lithium, aripip-
razole
Bisoprolol 2.5 mg/
daily, lisinopril 20 
mg/daily
2nd course; 
1st session
Chronic obstructive 
pulmonary disease, 
hypertension
None
De Wolf 
2015 
(4)
F Unknown 67 The recurrent 
major depres-
sive disorder
Fluvoxamine 
300 mg daily, 
mirtazapine 15 
mg daily
Unknown Unknown 
(2nd?); 24 
sessions 
(mECT*)
Oropharyngeal 
cancer
Unknown
*meCt – maintenance electroconvulsive therapy.
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subo cardiomyopathy is supported by the burst activity of 
norepinephrine neurons not only due to ECT, but also due 
to clozapine and nicotine use, as was shown in the locus 
coeruleus in an animal model (23). How these therapies 
interact to alter levels of catecholamine remains unclear. 
Reports on ECT-induced takotsubo cardiomyopathy show 
that antidepressants alter the neuronal reuptake of plasma 
catecholamine and facilitate myocardial stunning by in-
creasing local catecholamine levels (Table 1).
Adrenergic blockade before, during, and after ECT mini-
mizes the risk of takotsubo cardiomyopathy recurrence (5). 
There are a few patients who underwent successful retrials 
of ECT after having developed takotsubo cardiomyopathy 
(6). Takotsubo cardiomyopathy treatment includes beta 
blockers during the period of ventricular recovery (18), and 
beta blockers have been shown in animal models to im-
prove left ventricular ejection fraction (24). There are three 
reports on the concomitant use of beta blockers in pa-
tients who develop takotsubo cardiomyopathy, similar to 
our case (5,7,12). Patients may be predisposed to develop 
takotsubo cardiomyopathy by conditions that raise base-
line catecholamine level (17,19). Both caffeine and nicotine 
elevate catecholamine blood levels (25), and our patient’s 
caffeine and nicotine use could have precipitated a car-
diovascular accident. In this case, simultaneous effects of 
clozapine, caffeine, nicotine, and ECT, along with male sex, 
seem to have overpowered the protective effect of beta 
blockers on takotsubo cardiomyopathy development.
In conclusion, our case shows that takotsubo cardiomyo-
pathy can occur as a rare complication of ECT in a male 
psychotic patient, despite the concomitant beta-block-
ade treatment. Clinical understanding of rare cardiac ECT 
complications could improve early recognition of patients 
at risk for takotsubo cardiomyopathy and ensure safe ECT 
protocols.
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